[P1]	O
Pentostatin	O
,	O
Cyclophosphamide	O
and	O
Rituximab	O
Followed	O
by	O
Alemtuzumab	O
[P2]	O
for	O
Relapsed	O
or	O
Refractory	O
Chronic	O
Lymphocytic	O
Leukemia	O
:	O

A	O
Phase	O
2	O
Trial	O
of	O
the	O
ECOG	O
-	O
ACRIN	O
Cancer	O
Research	O
Group	O
(	O
E2903	O
)	O
[P1]	O
Pentostatin	O
,	O
Cyclophosphamide	O
and	O
Rituximab	O
Followed	O
by	O
Alemtuzumab	O
[P2]	O
for	O
Relapsed	O
or	O
Refractory	O
Chronic	O
Lymphocytic	O
Leukemia	O
:	O

[P1]	O
Pentostatin	O
,	O
Cyclophosphamide	O
and	O
Rituximab	O
Followed	O
by	O
Alemtuzumab	O
[P2]	O
for	O
Relapsed	O
or	O
Refractory	O
Chronic	O
Lymphocytic	O
Leukemia	O
:	O

[P1]	O
Pentostatin	O
,	O
Cyclophosphamide	O
and	O
Rituximab	O
Followed	O
by	O
Alemtuzumab	O
[P2]	O
for	O
Relapsed	O
or	O
Refractory	O
Chronic	O
Lymphocytic	O
Leukemia	O
:	O

NY	O
New	O
York	O
NY	O
NatalieSCallander	O
NatalieSCallander	O
Natalie	O
S	O
Callander	O
GeraldGross	O
GeraldGross	O
Gerald	O
Gross	O
MartinSTallman	O
MartinSTallman	O
Martin	O
S	O
Tallman	O
[P1]	O
Pentostatin	O
,	O
Cyclophosphamide	O
and	O
Rituximab	O
Followed	O
by	O
Alemtuzumab	O
[P2]	O
for	O
Relapsed	O
or	O
Refractory	O
Chronic	O
Lymphocytic	O
Leukemia	O
:	O

20	O
Encouraged	O
by	O
these	O
results	O
we	O
designed	O
and	O
activated	O
a	O
phase	O
2	O
trial	O
,	O
E2903	O
,	O
for	O
R	O
/	O
R	O
CLL	O
that	O
incorporated	O
6	B-arm_dosage
cycles	I-arm_dosage
of	O
[P1]	O
PCR	O
[P2]	O
,	O
followed	O
by	O
an	O
anti	O
-	O
CD52	O
antibody	O
,	O
alemtuzumab	O
,	O
as	O
consolidation	B-arm_dosage
.	O

20	O
Encouraged	O
by	O
these	O
results	O
we	O
designed	O
and	O
activated	O
a	O
phase	O
2	O
trial	O
,	O
E2903	O
,	O
for	O
R	O
/	O
R	O
CLL	O
that	O
incorporated	O
6	B-arm_dosage
cycles	I-arm_dosage
of	O
PCR	O
,	O
[P1]	O
followed	O
by	O
an	O
anti	O
-	O
CD52	O
antibody	O
,	O
alemtuzumab	O
[P2]	O
,	O
as	O
consolidation	B-arm_dosage
.	O

For	O
subsequent	B-arm_dosage
cycles	I-arm_dosage
(	I-arm_dosage
2	I-arm_dosage
-	I-arm_dosage
6	I-arm_dosage
)	I-arm_dosage
rituximab	I-arm_dosage
was	I-arm_dosage
given	I-arm_dosage
at	I-arm_dosage
a	I-arm_dosage
dose	I-arm_dosage
of	I-arm_dosage
375	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
on	O
the	O
same	O
day	O
as	O
the	O
pentostatin	O
and	O
cyclophosphamide	O
(	O
[P1]	O
PCR	O
[P2]	O
)	O
.	O

This	O
[P1]	O
PCR	O
regimen	O
[P2]	O
was	O
given	B-arm_dosage
on	I-arm_dosage
a	I-arm_dosage
21-day	I-arm_dosage
6-cycle	I-arm_dosage
schedule	I-arm_dosage
.	O

[P1]	O
Bactrim	O
DS	O
[P2]	O
(	O
QOD	B-arm_dosage
)	O
and	O
acyclovir	O
(	O
800	B-arm_dosage
mg	I-arm_dosage
BID	I-arm_dosage
)	O
were	O
administered	B-arm_dosage
during	I-arm_dosage
the	I-arm_dosage
entire	I-arm_dosage
course	I-arm_dosage
of	O
PCR	O
,	O
and	O
alemtuzumab	O
administration	O
.	O

Bactrim	O
DS	O
(	O
QOD	B-arm_dosage
)	O
and	O
[P1]	O
acyclovir	O
[P2]	O
(	O
800	B-arm_dosage
mg	I-arm_dosage
BID	I-arm_dosage
)	O
were	O
administered	B-arm_dosage
during	I-arm_dosage
the	I-arm_dosage
entire	I-arm_dosage
course	I-arm_dosage
of	O
PCR	O
,	O
and	O
alemtuzumab	O
administration	O
.	O

Bactrim	O
DS	O
(	O
QOD	B-arm_dosage
)	O
and	O
acyclovir	O
(	O
800	B-arm_dosage
mg	I-arm_dosage
BID	I-arm_dosage
)	O
were	O
administered	B-arm_dosage
during	I-arm_dosage
the	I-arm_dosage
entire	I-arm_dosage
course	I-arm_dosage
of	O
[P1]	O
PCR	O
[P2]	O
,	O
and	O
alemtuzumab	O
administration	O
.	O

Bactrim	O
DS	O
(	O
QOD	B-arm_dosage
)	O
and	O
acyclovir	O
(	O
800	B-arm_dosage
mg	I-arm_dosage
BID	I-arm_dosage
)	O
were	O
administered	B-arm_dosage
during	I-arm_dosage
the	I-arm_dosage
entire	I-arm_dosage
course	I-arm_dosage
of	O
PCR	O
,	O
and	O
[P1]	O
alemtuzumab	O
[P2]	O
administration	O
.	O

The	O
first	O
cycle	O
of	O
[P1]	O
PCR	O
[P2]	O
was	O
to	O
be	O
administered	O
at	O
full	O
dose	O
regardless	O
of	O
preexisting	O
cytopenias	O
.	O

During	B-arm_dosage
cycle	I-arm_dosage
one	I-arm_dosage
[P1]	O
G	O
-	O
CSF	O
(	O
Neupogen	O
)	O
[P2]	O
was	O
administered	B-arm_dosage
SQ	I-arm_dosage
daily	I-arm_dosage
,	I-arm_dosage
beginning	I-arm_dosage
two	I-arm_dosage
days	I-arm_dosage
after	I-arm_dosage
treatment	I-arm_dosage
for	I-arm_dosage
10	I-arm_dosage
consecutive	I-arm_dosage
days	I-arm_dosage
or	O
until	O
the	O
neutrophil	O
count	O
was	O
greater	O
than	O
1.0	O
Ã—	O
10	O
9	O
/L	O
for	O
2	O
consecutive	O
days	O
.	O

[P1]	O
Patients	O
achieving	O
a	O
CR	O
or	O
nPR	O
after	O
PCR	O
[P2]	O
were	O
then	O
observed	O
during	O
an	O
8	O
week	O
treatmentfree	O
interval	O
after	O
which	O
a	O
bone	O
marrow	O
study	O
was	O
performed	O
for	O
pathologic	O
confirmation	O
of	O
response	O
.	O

After	O
confirmation	O
of	O
response	O
,	O
[P1]	O
alemtuzumab	O
[P2]	O
(	B-arm_dosage
30	I-arm_dosage
mg	I-arm_dosage
SQ	I-arm_dosage
)	I-arm_dosage
was	I-arm_dosage
administered	I-arm_dosage
three	I-arm_dosage
times	I-arm_dosage
a	I-arm_dosage
week	I-arm_dosage
(	I-arm_dosage
TIW	I-arm_dosage
)	I-arm_dosage
for	I-arm_dosage
four	I-arm_dosage
weeks	I-arm_dosage
.	O

39,40	O
The	O
four	O
week	O
course	O
for	O
CR	O
or	O
nPR	O
patients	O
as	O
opposed	O
to	O
the	O
18	O
week	O
course	O
for	O
a	O
lesser	O
response	O
was	O
based	O
upon	O
the	O
concept	O
that	O
robust	O
responding	O
patients	O
would	O
need	O
less	O
intensive	O
exposure	O
to	O
[P1]	O
alemtuzumab	O
[P2]	O
and	O
have	O
less	O
infectious	O
complications	O
.	O

41	O
Patients	O
achieving	O
a	O
PR	O
or	O
stable	O
disease	O
(	O
SD	O
)	O
after	O
six	O
cycles	O
or	O
progressive	O
disease	O
(	O
PD	O
)	O
after	O
at	O
least	O
2	O
cycles	O
of	O
PCR	O
received	O
[P1]	O
alemtuzumab	O
[P2]	O
(	O
30	O
mg	O
SQ	O
TIW	O
)	O
for	O
18	O
weeks	O
after	O
a	O
treatment	O
-	O
free	O
period	O
determined	O
by	O
the	O
investigator	O
.	O

CR	O
and	O
nPR	O
response	O
criteria	O
,	O
determined	O
after	O
completion	O
of	O
[P1]	O
PCR	O
[P2]	O
and	O
after	O
the	O
8	O
week	O
hiatus	O
noted	O
above	O
,	O
was	O
defined	O
by	O
the	O
1996	O
CLL	O
Working	O
Group	O
criteria	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
response	O
rate	O
to	O
[P1]	O
PCR	O
[P2]	O
.	O

Landmark	O
analysis	O
at	O
6	O
months	O
was	O
done	O
when	O
patients	O
had	O
scheduled	O
[P1]	O
PCR	O
[P2]	O
treatment	O
cycles	O
completed	O
and	O
was	O
utilized	O
to	O
compare	O
the	O
overall	O
survival	O
between	O
responders	O
and	O
non	O
-	O
responders	O
.	O

In	O
a	O
multivariate	O
logistic	O
model	O
only	O
CD	O
38	O
<	O
20	O
%	O
was	O
significantly	O
associated	O
with	O
a	O
[P1]	O
PCR	O
[P2]	O
response	O
(	O
p=0.01	O
)	O
.	O

Treatment	O
-	O
related	O
toxicities	O
during	O
[P1]	O
PCR	O
[P2]	O
and	O
alemtuzumab	O
were	O
those	O
expected	O
in	O
patients	O
with	O
R	O
/	O
R	O
CLL	O
receiving	O
CIT	O
(	O
Table	O
2	O
)	O
.	O

Treatment	O
-	O
related	O
toxicities	O
during	O
PCR	O
and	O
[P1]	O
alemtuzumab	O
[P2]	O
were	O
those	O
expected	O
in	O
patients	O
with	O
R	O
/	O
R	O
CLL	O
receiving	O
CIT	O
(	O
Table	O
2	O
)	O
.	O

Anemia	O
,	O
thrombocytopenia	O
and	O
neutropenia	O
were	O
observed	O
in	O
16	O
%	O
,	O
34	O
%	O
and	O
60	O
%	O
,	O
respectively	O
,	O
during	O
[P1]	O
PCR	O
treatment	O
[P2]	O
.	O

The	O
worst	O
-	O
degree	O
of	O
non	O
-	O
hematologic	O
treatment	O
-	O
related	O
toxicities	O
during	O
[P1]	O
PCR	O
treatment	O
[P2]	O
were	O
grades	O
3	O
-	O
4	O
in	O
47	O
patients	O
(	O
47	O
%	O
)	O
and	O
grade	O
5	O
in	O
5	O
patients	O
(	O
5	O
%	O
)	O
.	O

There	O
were	O
5	O
treatment	O
-	O
related	O
deaths	O
during	O
the	O
[P1]	O
PCR	O
therapy	O
[P2]	O
including	O
multiorgan	O
failure	O
(	O
1	O
)	O
,	O
ARDS	O
,	O
non	O
-	O
CMV	O
(	O
1	O
)	O
,	O
infection	O
(	O
1	O
)	O
,	O
pneumonitis	O
(	O
2	O
)	O
.	O

During	O
the	O
[P1]	O
alemtuzumab	O
treatment	O
arms	O
[P2]	O
,	O
pain	O
at	O
the	O
injection	O
site	O
,	O
fever	O
,	O
and	O
myalgias	O
were	O
grades	O
I	O
or	O
2	O
.	O

One	O
patient	O
with	O
a	O
grade	O
4	O
local	O
injection	O
site	O
reaction	O
was	O
removed	O
from	O
study	O
after	O
2	O
doses	O
of	O
[P1]	O
alemtuzumab	O
[P2]	O
.	O

One	O
patient	O
developed	O
CMV	O
positive	O
serology	O
during	O
the	O
4-week	O
[P1]	O
alemtuzumab	O
[P2]	O
treatment	O
and	O
two	O
patients	O
in	O
subsequent	O
follow	O
-	O
up	O
.	O

Two	O
patients	O
developed	O
CMV	O
positive	O
serology	O
during	O
the	O
18-week	O
[P1]	O
alemtuzumab	O
treatment	O
[P2]	O
,	O
two	O
of	O
whom	O
developed	O
pneumonia	O
.	O